Renovorx Inc (RNXT)

$0.91 +0.01 (0.90%)
Market Cap 33.06M
Revenue (ttm) 40,000.00
Net Income (ttm) -8.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -22,025.00%
Debt to Equity Ratio 0.00
Volume 113,000
Avg Vol 245,778
Day's Range N/A - N/A
Shares Out 36.65M
Stochastic %K 17%
Beta 1.31
Analysts Strong Sell
Price Target $6.75

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 284 4433
Fax: 650 397 4433
Address:
2570 West El Camino Real, Suite 320, Mountain View, United States
Rnxtsavior
Rnxtsavior Feb. 26 at 11:27 AM
$RNXT .88 premarket. Do we hit .70's today? Only the Sheeny man knows.
0 · Reply
Wolfietrader
Wolfietrader Feb. 25 at 4:55 PM
$RNXT down down down. Just no interest here
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 25 at 3:43 PM
$RNXT This is selling not buying. Prop up on small volume while dumping bigger chunks. It's toast
0 · Reply
enzomassimi
enzomassimi Feb. 25 at 2:36 PM
$RNXT go
0 · Reply
enzomassimi
enzomassimi Feb. 25 at 2:09 PM
$RNXT GO TODAY !
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 24 at 7:34 PM
$RNXT. 80's. Can't get rid of me yet. I will do the same deal in a few days with the .70's and so on...and so on.
0 · Reply
victory369
victory369 Feb. 24 at 7:13 PM
$RNXT This garbage still trading not delist yet ? 🥺
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 24 at 2:12 PM
$RNXT 100% this will touch 80's TODAY or I will never post here again.
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 23 at 9:03 PM
$RNXT large chunks dumped at the end of day. Good sign?
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 23 at 6:16 PM
$RNXT I'm going to says this for the paid pumpers.... It's going down because of the market today.
1 · Reply
Latest News on RNXT
RenovoRx Establishes RenovoCath® Medical Advisory Board

Feb 10, 2026, 8:30 AM EST - 16 days ago

RenovoRx Establishes RenovoCath® Medical Advisory Board

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

Feb 5, 2026, 8:30 AM EST - 21 days ago

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

Feb 4, 2026, 8:30 AM EST - 22 days ago

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

Jan 28, 2026, 8:30 AM EST - 4 weeks ago

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

Jan 20, 2026, 8:30 AM EST - 5 weeks ago

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

Jan 14, 2026, 8:30 AM EST - 6 weeks ago

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

Jan 8, 2026, 8:30 AM EST - 7 weeks ago

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

Dec 11, 2025, 8:30 AM EST - 2 months ago

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript

Dec 9, 2025, 2:57 PM EST - 2 months ago

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

Dec 1, 2025, 8:30 AM EST - 3 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

Nov 19, 2025, 8:30 AM EST - 3 months ago

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

Nov 13, 2025, 4:05 PM EST - 3 months ago

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

Nov 6, 2025, 8:30 AM EST - 4 months ago

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

Nov 4, 2025, 8:30 AM EST - 4 months ago

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

Oct 27, 2025, 8:30 AM EDT - 4 months ago

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Oct 9, 2025, 8:30 AM EDT - 5 months ago

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

Sep 25, 2025, 8:30 AM EDT - 5 months ago

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

Sep 11, 2025, 8:30 AM EDT - 6 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

Aug 20, 2025, 8:30 AM EDT - 6 months ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

Aug 14, 2025, 4:05 PM EDT - 6 months ago

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

Aug 6, 2025, 8:30 AM EDT - 7 months ago

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

Jul 28, 2025, 8:30 AM EDT - 7 months ago

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

Jul 14, 2025, 8:30 AM EDT - 8 months ago

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 9:07 PM EDT - 10 months ago

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025, 4:05 PM EDT - 10 months ago

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025, 8:30 AM EDT - 10 months ago

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025, 8:30 AM EDT - 10 months ago

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

May 1, 2025, 8:30 AM EDT - 10 months ago

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

Apr 29, 2025, 8:30 AM EDT - 10 months ago

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Apr 16, 2025, 8:30 AM EDT - 11 months ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Apr 4, 2025, 8:30 AM EDT - 11 months ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Apr 1, 2025, 8:30 AM EDT - 11 months ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Mar 28, 2025, 8:00 AM EDT - 11 months ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Mar 26, 2025, 8:00 AM EDT - 1 year ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

Mar 20, 2025, 8:00 AM EDT - 1 year ago

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

Mar 19, 2025, 8:00 AM EDT - 1 year ago

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Feb 26, 2025, 8:00 AM EST - 1 year ago

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Feb 13, 2025, 8:00 AM EST - 1 year ago

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 11, 2025, 7:00 AM EST - 1 year ago

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 8:49 PM EST - 1 year ago

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Proposed Public Offering

Feb 6, 2025, 4:05 PM EST - 1 year ago

RenovoRx Announces Proposed Public Offering

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

Feb 5, 2025, 2:14 AM EST - 1 year ago

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Jan 27, 2025, 8:00 AM EST - 1 year ago

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Jan 8, 2025, 8:00 AM EST - 1 year ago

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Dec 30, 2024, 8:00 AM EST - 1 year ago

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Nov 20, 2024, 8:45 AM EST - 1 year ago

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Sep 25, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Sep 19, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

Aug 27, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

Rnxtsavior
Rnxtsavior Feb. 26 at 11:27 AM
$RNXT .88 premarket. Do we hit .70's today? Only the Sheeny man knows.
0 · Reply
Wolfietrader
Wolfietrader Feb. 25 at 4:55 PM
$RNXT down down down. Just no interest here
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 25 at 3:43 PM
$RNXT This is selling not buying. Prop up on small volume while dumping bigger chunks. It's toast
0 · Reply
enzomassimi
enzomassimi Feb. 25 at 2:36 PM
$RNXT go
0 · Reply
enzomassimi
enzomassimi Feb. 25 at 2:09 PM
$RNXT GO TODAY !
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 24 at 7:34 PM
$RNXT. 80's. Can't get rid of me yet. I will do the same deal in a few days with the .70's and so on...and so on.
0 · Reply
victory369
victory369 Feb. 24 at 7:13 PM
$RNXT This garbage still trading not delist yet ? 🥺
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 24 at 2:12 PM
$RNXT 100% this will touch 80's TODAY or I will never post here again.
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 23 at 9:03 PM
$RNXT large chunks dumped at the end of day. Good sign?
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 23 at 6:16 PM
$RNXT I'm going to says this for the paid pumpers.... It's going down because of the market today.
1 · Reply
Rnxtsavior
Rnxtsavior Feb. 23 at 3:24 PM
$RNXT Yikes. 30k chunk dumped at .90 .80's today? All leading to a big fat sheeny man reverse split.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 22 at 8:33 PM
$RNXT Current Stock Price: $0.91
1 · Reply
victory369
victory369 Feb. 20 at 10:40 AM
$RNXT This stock is dead
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 10:08 PM
$RNXT RSI: 47.82, MACD: -0.0040 Vol: 0.04, MA20: 0.97, MA50: 0.96 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Wolfietrader
Wolfietrader Feb. 19 at 7:35 PM
$RNXT go up for goodness sakes!
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 19 at 7:23 PM
$RNXT Maybe .80's today. Prop up time is over. About to
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 19 at 4:11 PM
$RNXT Lol.. told you. Touching .80's tomorrow. Zero catalyst. Maybe an insider should buy a few shares so someone can point it out on boards...lol. Sheeny man is getting you all.
0 · Reply
Rnxtsavior
Rnxtsavior Feb. 19 at 12:36 PM
$RNXT Low 90's today... fake propping up going on in this one for days.. will fall
0 · Reply
Mortz20
Mortz20 Feb. 18 at 5:27 PM
$RNXT
0 · Reply
enzomassimi
enzomassimi Feb. 18 at 2:43 PM
$RNXT BUY
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Feb. 18 at 5:48 AM
$RNXT or MTEKW ?
0 · Reply
VolatilityPremiums
VolatilityPremiums Feb. 17 at 12:45 PM
$RNXT Pre-revenue medtech; early-stage.
0 · Reply